POINT Biopharma Global Inc.

GX Acquisition Corp. II, trading under the ticker RACA on Nasdaq and sponsored by GX Sponsor II LLC, completed its de-SPAC transaction with POINT Biopharma Global Inc. through a business combination reported in an 8-K filed June 30, 2021. The SPAC, which conducted its IPO in 2021, targeted the healthcare and life sciences sector and served as the vehicle to bring POINT Biopharma — a clinical-stage radiopharmaceutical company developing targeted radioligand therapies for oncology — to the public markets. Following the closing, the combined company traded under the ticker PNT on Nasdaq. Sign up at SpacDesk for full filing history, sponsor profiles, and deal analytics across the entire SPAC universe.